Brief: Biontech To Collaborate With Autolus In CAR-T Cell Therapy, Invests $200 Mln In Co

Autolus Therapeutics

08/02/2024 10:49

Feb 8 (Reuters) - BioNTech SE  22UAy.DE :
    * BIONTECH AND AUTOLUS ANNOUNCE STRATEGIC CAR-T CELL THERAPY
COLLABORATION TO ADVANCE PIPELINE AND EXPAND LATE-STAGE PROGRAMS
    * AGREES TO INVEST $200 MILLION IN AUTOLUS
    * ANNOUNCED A STRATEGIC COLLABORATION AIMED AT ADVANCING
BOTH
COMPANIES' AUTOLOGOUS CAR-T PROGRAMS TOWARDS COMMERCIALIZATION
    * WILL HAVE A RIGHT TO APPOINT A DIRECTOR TO BOARD OF
AUTOLUS
    * SECURES RIGHT TO UTILIZE AUTOLUS' MANUFACTURING CAPACITY
TO
ACCELERATE DEVELOPMENT OF BNT211
    * HAS CO-COMMERCIALIZATION OPTIONS FOR AUTOLUS' AUTO1/22 AND
AUTO6NG PROGRAMS
    * HAS OPTION TO ACCESS A SUITE OF AUTOLUS TARGET BINDERS AND
CELL
PROGRAMMING TECHNOLOGIES
    * BIONTECH SE TO MAKE A CASH PAYMENT OF $50 MILLION

Source text for Eikon:  ID:nGNE4qfZFF 
Further company coverage:  22UAy.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))